Recent advances in the treatment of B-cell lymphoma

Por Habermann, Thomas M
Publicado em 2009

Epidemiology of Marginal Zone Lymphoma

Por Cerhan, James R., Habermann, Thomas M.
Publicado no Ann Lymphoma (2021)

Patients With Celiac Disease and B-Cell Lymphoma Have a Better Prognosis Than Those With T-Cell Lymphoma

Por Halfdanarson, Thorvardur R., Rubio–Tapia, Alberto, Ristow, Kay M., Habermann, Thomas M., Murray, Joseph A., Inwards, David J.
Publicado em 2010

The Search for Surrogate Endpoints in Trials in Diffuse Large B‐Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma Project

Por Sargent, Daniel J., Shi, Qian, Flowers, Christopher R., Schmitz, Norbert, Habermann, Thomas M., Flament, Jocelyne, Fu, Tommy, Coiffier, Bertrand
Publicado no Oncologist (2017)

Elevated Serum Lactate in Patients With Lymphoma: It Is Not Always Infection

Por Ruan, Gordon J., Gandhi, Sangeetha, Abeykoon, Jithma P., Schram, Susan, Habermann, Thomas M., Sandefur, Benjamin J., Witzig, Thomas E.
Publicado no Mayo Clin Proc Innov Qual Outcomes (2021)

If you feed them, they will come: A prospective study of the effects of complimentary food on attendance and physician attitudes at medical grand rounds at an academic medical cent...

Por Segovis, Colin M, Mueller, Paul S, Rethlefsen, Melissa L, LaRusso, Nicholas F, Litin, Scott C, Tefferi, Ayalew, Habermann, Thomas M
Publicado em 2007

Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial

Por Advani, Ranjana H., Hong, Fangxin, Horning, Sandra J., Kahl, Brad S., Manola, Judith, Swinnen, Lode J., Habermann, Thomas M., Ganjoo, Kristen
Publicado em 2011

Patterns of Growth Factor Usage and Febrile Neutropenia Among Older Patients with Diffuse Large B-Cell Non-Hodgkin Lymphoma Treated with CHOP or R-CHOP: The Intergroup Experience (...

Por Morrison, Vicki A., Weller, Edie A., Habermann, Thomas M., Li, Shuli, Fisher, Richard I., Cheson, Bruce D., Peterson, Bruce A.
Publicado no Leuk Lymphoma (2016)

Risk for Significant Kidney Function Decline After Acute Kidney Injury in Adults With Hematologic Malignancy

Por May, Heather P., Barreto, Erin F., Mara, Kristin C., McCullough, Kristen B., Patnaik, Mrinal S., Leung, Nelson, Habermann, Thomas M.
Publicado no Kidney Int Rep (2021)

Antioxidant Intake from Fruits, Vegetables and Other Sources and Risk of Non-Hodgkin Lymphoma: The Iowa Women's Health Study

Por Thompson, Carrie A., Habermann, Thomas M., Wang, Alice H., Vierkant, Robert A., Folsom, Aaron R., Ross, Julie A., Cerhan, James R.
Publicado em 2010

The Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) with Everolimus Results in Clinical Responses and Mobilization of CLL Cells into...

Por Zent, Clive S., LaPlant, Betsy R., Johnston, Patrick B., Call, Timothy G., Habermann, Thomas M., Micallef, Ivana N., Witzig, Thomas E.
Publicado em 2010

SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma

Por Chen, Linfeng, Monti, Stefano, Juszczynski, Przemyslaw, Daley, John, Chen, Wen, Witzig, Thomas E., Habermann, Thomas M., Kutok, Jeffery L., Shipp, Margaret A.
Publicado em 2008

FDG-PET Report Interpretation as Predictor of Outcome in Diffuse Large B-Cell Lymphoma Including Analysis of “Indeterminate” Reports

Por Thomas, Alexandra, Gingrich, Roger D., Smith, Brian J., Jacobus, Laura, Ristow, Kay, Allmer, Cristine, Maurer, Matthew J., Habermann, Thomas M., Link, Brian K.
Publicado em 2010

Bevacizumab and CHOP (A-CHOP) in Combination for Patients with Peripheral T-Cell or Natural Killer Cell Neoplasms: An Eastern Cooperative Group Study (E2404)

Por Ganjoo, Kristen, Hong, Fangxin, Horning, Sandra J., Gascoyne, Randy D., Natkunam, Yasodha, Swinnen, Lode J., Habermann, Thomas M., Kahl, Brad S., Advani, Ranjana H.
Publicado em 2013

Maintenance Rituximab After Cyclophosphamide, Vincristine, and Prednisone Prolongs Progression-Free Survival in Advanced Indolent Lymphoma: Results of the Randomized Phase III ECOG...

Por Hochster, Howard, Weller, Edie, Gascoyne, Randy D., Habermann, Thomas M., Gordon, Leo I., Ryan, Theresa, Zhang, Lijun, Colocci, Natalia, Frankel, Stanley, Horning, Sandra J.
Publicado em 2009

Risk of Cutaneous T-Cell Lymphoma in Patients With Chronic Lymphocytic Leukemia and Other Subtypes of Non-Hodgkin Lymphoma

Por Chang, Timothy W., Weaver, Amy L., Shanafelt, Tait D., Habermann, Thomas M., Wriston, Cooper C., Cerhan, James R., Call, Timothy G., Brewer, Jerry D.
Publicado no Int J Dermatol (2017)

Response-Adapted Therapy for Aggressive non-Hodgkin's Lymphomas based on early [18F] FDG-PET Scanning: ECOG-ACRIN Cancer Research Group Study (E3404)

Por Swinnen, Lode J., Li, Hailun, Quon, Andrew, Gascoyne, Randy, Hong, Fangxin, Ranheim, Erik A., Habermann, Thomas M., Kahl, Brad S., Horning, Sandra J., Advani, Ranjana H.
Publicado no Br J Haematol (2015)

Fluorodeoxyglucose‐Positron Emission Tomography Predicts Bone Marrow Involvement in the Staging of Follicular Lymphoma

Por St‐Pierre, Frédérique, Broski, Stephen M., LaPlant, Betsy R., Maurer, Matthew J., Ristow, Kay, Thanarajasingam, Gita, Macon, William R., Habermann, Thomas M., Witzig, Thomas E.
Publicado no Oncologist (2020)

Anthropometric, medical history and lifestyle risk factors for myeloproliferative neoplasms in The Iowa Women’s Health Study (IWHS) cohort

Por Leal, Alexis D., Thompson, Carrie A., Wang, Alice H., Vierkant, Robert A., Habermann, Thomas M., Ross, Julie A., Mesa, Ruben A., Virnig, Beth A., Cerhan, James R.
Publicado em 2013

Hormonal and Reproductive Factors and Risk of Myeloproliferative Neoplasms in Postmenopausal Women

Por Leal, Alexis D., Thompson, Carrie A., Wang, Alice H., Vierkant, Robert A., Habermann, Thomas M., Ross, Julie A., Mesa, Ruben A., Virnig, Beth A., Cerhan, James R.
Publicado no Cancer Epidemiol Biomarkers Prev (2015)